Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>(R)-(-)-JQ1 Enantiomer

(R)-(-)-JQ1 Enantiomer

Katalog-Nr.GC63791

(R)-(-)-JQ1 Enantiomer ist das Stereoisomer von (+)-JQ1. (+)-JQ1 verringert stark die Expression beider BRD4-Zielgene, wÄhrend (R)-(-)-JQ1-Enantiomer keine Wirkung hat.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-(-)-JQ1 Enantiomer Chemische Struktur

Cas No.: 1268524-71-5

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
81,00 $
Auf Lager
2 mg
53,00 $
Auf Lager
5 mg
99,00 $
Auf Lager
10 mg
172,00 $
Auf Lager
50 mg
591,00 $
Auf Lager
100 mg
1.080,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.

(R)-(-)-JQ1 Enantiomer shows no significant interaction with any bromodomain. Besides, (R)-(-)-JQ1 Enantiomer is comparatively inactive in nuclear protein in testis (NUT) midline carcinoma (NMC)[1].

[1]. Filippakopoulos, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
[2]. Mahe M, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018 Apr;10(4). pii: e8163.

Bewertungen

Review for (R)-(-)-JQ1 Enantiomer

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-(-)-JQ1 Enantiomer

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.